Jazz Pharmaceuticals PLC $JAZZ Shares Purchased by Bank of Montreal Can

Bank of Montreal Can raised its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 2.6% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 337,162 shares of the specialty pharmaceutical company’s stock after purchasing an additional 8,687 shares during the quarter. Bank of Montreal Can owned about 0.55% of Jazz Pharmaceuticals worth $44,438,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Swiss National Bank grew its holdings in shares of Jazz Pharmaceuticals by 1.1% during the third quarter. Swiss National Bank now owns 111,400 shares of the specialty pharmaceutical company’s stock worth $14,683,000 after buying an additional 1,200 shares during the last quarter. Pinnacle Associates Ltd. raised its stake in Jazz Pharmaceuticals by 2.9% during the 3rd quarter. Pinnacle Associates Ltd. now owns 11,120 shares of the specialty pharmaceutical company’s stock valued at $1,466,000 after acquiring an additional 312 shares during the last quarter. Natixis Advisors LLC lifted its position in Jazz Pharmaceuticals by 25.2% during the 3rd quarter. Natixis Advisors LLC now owns 26,549 shares of the specialty pharmaceutical company’s stock worth $3,499,000 after acquiring an additional 5,342 shares during the period. Blair William & Co. IL lifted its position in Jazz Pharmaceuticals by 5.0% during the 3rd quarter. Blair William & Co. IL now owns 2,107 shares of the specialty pharmaceutical company’s stock worth $278,000 after acquiring an additional 101 shares during the period. Finally, First Trust Advisors LP grew its stake in shares of Jazz Pharmaceuticals by 17.6% in the 3rd quarter. First Trust Advisors LP now owns 241,870 shares of the specialty pharmaceutical company’s stock valued at $31,878,000 after purchasing an additional 36,246 shares during the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have recently issued reports on JAZZ. Royal Bank Of Canada boosted their target price on Jazz Pharmaceuticals from $191.00 to $195.00 and gave the company an “outperform” rating in a report on Wednesday, February 25th. Piper Sandler reiterated an “overweight” rating and issued a $219.00 price objective (up from $147.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, December 10th. Robert W. Baird boosted their price objective on shares of Jazz Pharmaceuticals from $160.00 to $209.00 and gave the company an “outperform” rating in a research note on Tuesday, November 18th. Needham & Company LLC upped their price objective on shares of Jazz Pharmaceuticals from $210.00 to $235.00 and gave the stock a “buy” rating in a research report on Monday, January 12th. Finally, Morgan Stanley raised their target price on shares of Jazz Pharmaceuticals from $225.00 to $226.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. Thirteen research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $214.38.

Jazz Pharmaceuticals Stock Down 2.8%

JAZZ opened at $180.32 on Friday. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.86 and a quick ratio of 1.67. Jazz Pharmaceuticals PLC has a 12 month low of $95.49 and a 12 month high of $198.00. The stock has a market capitalization of $11.10 billion, a P/E ratio of -30.20, a P/E/G ratio of 0.33 and a beta of 0.22. The business has a 50 day simple moving average of $172.22 and a 200-day simple moving average of $155.61.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Tuesday, February 24th. The specialty pharmaceutical company reported $6.64 earnings per share for the quarter, topping analysts’ consensus estimates of $6.49 by $0.15. Jazz Pharmaceuticals had a positive return on equity of 6.87% and a negative net margin of 8.35%.The firm had revenue of $1.20 billion for the quarter, compared to analyst estimates of $1.17 billion. During the same quarter in the prior year, the company posted $6.51 earnings per share. Jazz Pharmaceuticals’s quarterly revenue was up 8.1% on a year-over-year basis. On average, equities analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Insider Activity at Jazz Pharmaceuticals

In related news, SVP Mary Elizabeth Henderson sold 5,343 shares of the business’s stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $194.49, for a total transaction of $1,039,160.07. Following the sale, the senior vice president owned 28,728 shares of the company’s stock, valued at approximately $5,587,308.72. The trade was a 15.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CAO Patricia Carr sold 1,287 shares of the company’s stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $182.94, for a total transaction of $235,443.78. Following the transaction, the chief accounting officer owned 6,512 shares in the company, valued at $1,191,305.28. The trade was a 16.50% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 68,015 shares of company stock valued at $13,037,486. Company insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.